MAPT and Alzheimer disease: We also measured NEV levels of AD biomarkers Aβ42, p‐Tau‐181, and total Tau due to the strong preclinical evidence demonstrating engagement of these disease‐specific pathways by NAD+ boosting molecules, such as NR and nicotinamide mononucleotide (NMN).